FDA Wants Another Trial Of Genta’s Genasense For CLL
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s complete response letter requesting another trial concludes the agency’s review of an amended NDA submitted after an unsuccessful appeal of a “not approvable” letter.